The Goldman Sachs Group Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $38.00
ArriVent BioPharma (NASDAQ:AVBP – Free Report) had its target price hoisted by The Goldman Sachs Group from $28.00 to $38.00 in a research note published on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock. Other equities research analysts have also issued reports about the stock. Oppenheimer reiterated an outperform […]
More Stories
Synchrony Financial (NYSE:SYF) Rating Increased to Buy at StockNews.com
Synchrony Financial (NYSE:SYF – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy”...
Analysts Set Paychex, Inc. (NASDAQ:PAYX) Target Price at $141.00
Paychex, Inc. (NASDAQ:PAYX – Get Free Report) has earned an average recommendation of “Reduce” from the twelve analysts that are...
Target (NYSE:TGT) Given New $102.00 Price Target at Barclays
Target (NYSE:TGT – Free Report) had its price target reduced by Barclays from $140.00 to $102.00 in a report released...
JPMorgan Chase & Co. Raises Victoria’s Secret & Co. (NYSE:VSCO) Price Target to $22.00
Victoria’s Secret & Co. (NYSE:VSCO – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $17.00...
Vitesse Energy (NYSE:VTS) Raised to “Hold” at Northland Capmk
Vitesse Energy (NYSE:VTS – Get Free Report) was upgraded by analysts at Northland Capmk to a “hold” rating in a...
Marvell Technology (NASDAQ:MRVL) Shares Down 3.1% After Insider Selling
Marvell Technology, Inc. (NASDAQ:MRVL – Get Free Report)’s stock price dropped 3.1% during mid-day trading on Tuesday following insider selling...